BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8:541-545. [PMID: 20298811 DOI: 10.1016/j.cgh.2010.02.023] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42:243-257. [PMID: 26151841 DOI: 10.1111/apt.13272] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 12.8] [Reference Citation Analysis]
2 Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis. 2012;205:757-762. [PMID: 22262790 DOI: 10.1093/infdis/jir852] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
3 Zhang K, Lin S, Wang M, Huang J, Zhu Y. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. Biomed Res Int 2020;2020:5728359. [PMID: 32596332 DOI: 10.1155/2020/5728359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 647] [Article Influence: 77.2] [Reference Citation Analysis]
5 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
7 Hsu Y, Mo L, Chang C, Wu M, Yang T, Kao J, Chen C, Tseng C, Tai C, Lin C, Wu C, Lin J. Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy: Clinical hepatitis B flare off entecavir. Journal of Gastroenterology and Hepatology 2017;32:1512-9. [DOI: 10.1111/jgh.13728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? Clin Mol Hepatol 2014;20:355-60. [PMID: 25548741 DOI: 10.3350/cmh.2014.20.4.355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014;60:1127-1134. [PMID: 24583247 DOI: 10.1016/j.jhep.2014.02.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
10 Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol 2013;3:301-12. [PMID: 25755518 DOI: 10.1016/j.jceh.2013.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
11 Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5:pii: F1000. [PMID: 27635243 DOI: 10.12688/f1000research.8983.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
12 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
13 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
14 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
15 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 951] [Article Influence: 179.3] [Reference Citation Analysis]
16 Wu D, Zhang S, Xie Z, Chen E, Rao Q, Liu X, Huang K, Yang J, Xiao L, Ji F, Jiang Z, Zhao Y, Ouyang X, Zhu D, Dai X, Hou Z, Liu B, Deng B, Zhou N, Gao H, Sun Z, Li L. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest 2020;130:2069-80. [PMID: 32175919 DOI: 10.1172/JCI130197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
18 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol 2014;20:10395-404. [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
19 Wei W, Wu Q, Zhou J, Kong Y, You H. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. Int J Environ Res Public Health 2015;12:10039-55. [PMID: 26308024 DOI: 10.3390/ijerph120810039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhu X, Chen L, Fan W, Lin MC, Tian L, Wang M, Lin S, Wang Z, Zhang J, Wang J. An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers. PLoS One. 2011;6:e21997. [PMID: 21779363 DOI: 10.1371/journal.pone.0021997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
21 Li HC, Huang EY, Su PY, Wu SY, Yang CC, Lin YS, Chang WC, Shih C. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog. 2010;6:e1001162. [PMID: 21060813 DOI: 10.1371/journal.ppat.1001162] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 7.8] [Reference Citation Analysis]
22 Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591-7. [PMID: 21769441 DOI: 10.1007/s12072-011-9299-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lei JH, Peng F, Chen Z, Xiao XQ. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis 2019;19:363. [PMID: 31039732 DOI: 10.1186/s12879-019-3988-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Wu HL, Kao JH, Chen TC, Wu WH, Liu CH, Su TH, Yang HC, Chen DS, Chen PJ, Liu CJ. Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. J Gastroenterol Hepatol 2014;29:1629-36. [PMID: 24730549 DOI: 10.1111/jgh.12606] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
25 Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol. 2014;20:16037-16052. [PMID: 25473156 DOI: 10.3748/wjg.v20.i43.16037] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
26 Tai DI, Tsay PK, Jeng WJ, Weng CC, Huang SF, Huang CH, Lin SM, Chiu CT, Chen WT, Wan YL. Differences in liver fibrosis between patients with chronic hepatitis B and C: evaluation by acoustic radiation force impulse measurements at 2 locations. J Ultrasound Med 2015;34:813-21. [PMID: 25911714 DOI: 10.7863/ultra.34.5.813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
27 Cui XJ, Cho YK, Song BC. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes. J Med Virol 2015;87:601-8. [PMID: 25612255 DOI: 10.1002/jmv.24117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gao FY, Liu Y, Li XS, Ye XQ, Sun L, Geng MF, Wang R, Liu HM, Zhou XB, Gu LL, Liu YM, Wan G, Wang XB. Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World J Gastroenterol. 2015;21:8373-8381. [PMID: 26217089 DOI: 10.3748/wjg.v21.i27.8373] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61:1407-1417. [PMID: 25178562 DOI: 10.1016/j.jhep.2014.08.033] [Cited by in Crossref: 147] [Cited by in F6Publishing: 127] [Article Influence: 21.0] [Reference Citation Analysis]
30 Bazinet M, Pântea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Dittmer U, Krawczyk A, Vaillant A. Benefit of transaminase elevations in establishing functional cure of HBV infection during nap-based combination therapy. J Viral Hepat 2021;28:817-25. [PMID: 33556206 DOI: 10.1111/jvh.13483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Guvenir M, Arikan A. Hepatitis B Virus: From Diagnosis to Treatment. Pol J Microbiol 2020;69:391-9. [PMID: 33574867 DOI: 10.33073/pjm-2020-044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Al-Mughales JA. Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi Arabia. J Med Virol 2016;88:1545-51. [PMID: 26895691 DOI: 10.1002/jmv.24503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
33 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
34 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Shen K, Shen L, Wang J, Jiang Z, Shen B. Understanding Amino Acid Mutations in Hepatitis B Virus Proteins for Rational Design of Vaccines and Drugs. Peptide and Protein Vaccines. Elsevier; 2015. pp. 131-53. [DOI: 10.1016/bs.apcsb.2015.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
37 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]